Skip to main content

Imipenem and Cilastatin Sodium Shortage

Last Updated: November 11, 2016
Status: Resolved

Products Affected - Description
    • Primaxin injection, Merck, 250 mg/ 250 mg, vial, 25 count, NDC 00006-3514-58
    • Primaxin injection, Merck, 250 mg/250 mg, ADD-Vantage vial, 25 count, NDC 00006-3551-58
    • Primaxin injection, Merck, 500 mg/500 mg, ADD-Vantage vial, 25 count, NDC 00006-3552-59
Reason for the Shortage
    • Fresenius Kabi had imipenem and cilastatin sodium injection on shortage due to increased demand.
    • Hospira had imipenem and cilastatin sodium injection on shortage due to manufacturing delays.
    • Merck has discontinued Primaxin ADD-Vantage vials as well as the 250 mg vials. Merck has Primaxin 500 mg vials available.
Available Products
    • Primaxin injection, Merck, 500 mg/500 mg, vial, 25 count, NDC 00006-3516-59
    • Imipenem and Cilastatin Sodium injection, Fresenius Kabi, 250 mg/250 mg, vial, 10 count, NDC 63323-0349-20
    • Imipenem and Cilastatin Sodium injection, Fresenius Kabi, 250 mg/250 mg, vial, 25 count, NDC 63323-0349-25
    • Imipenem and Cilastatin Sodium injection, Fresenius Kabi, 500 mg/500 mg, vial, 10 count, NDC 63323-0322-20
    • Imipenem and Cilastatin Sodium injection, Fresenius Kabi, 500 mg/500 mg, vial, 25 count, NDC 63323-0322-25
    • Imipenem and Cilastatin Sodium injection, Pfizer, 250 mg/ 250 mg, vial, 25 count, NDC 00409-3508-01
    • Imipenem and Cilastatin Sodium injection, Pfizer, 500 mg/500 mg, vial, 25 count, NDC 00409-3507-01

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated November 11, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 13, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer